drugset / Trial / NCT04425460
A Multi-center,Randomized,Double-blind,Placebo-controlled,Phase 3 Study Evaluating Favipiravir in Treatment of COVID19
Phase 3
Unknown
256 enrolled
Zhejiang Hisun Pharmaceutical Co. Ltd.
Opera CRO, a TIGERMED Group Company · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a multi-center, randomized, double-blind, placebo-controlled, phase III clinical study to evaluate the efficacy of Favipiravir combined with supportive care for adult patients with COVID-19-Moderate type.
Timeline
- Start
- 2020-06
- Primary completion
- 2020-08
- Completion
- 2020-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Favipiravir | Small molecule | 600 mg | — |